blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2134372

EP2134372 - MMP ACTIVATED VASCULAR DISRUPTING AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.12.2016
Database last updated on 19.07.2024
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
New state(s): TR
Updated state(s): MT		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
Incanthera Limited
76 King Street
Manchester
M2 4NH / GB
[2015/47]
Former [2013/16]For all designated states
Incanthera Limited
Institute of Cancer Therapeutics
Richmond Road
Bradford
BD7 1DP / GB
Former [2009/52]For all designated states
University of Bradford
Bradford
West Yorkshire BD7 1DP / GB
Inventor(s)01 / GILL, Jason
University of Bradford
Bradford West Yorkshire BD7 1DP / GB
02 / LOADMAN, Paul
University of Bradford
Bradford West Yorkshire BD7 1DP / GB
03 / FALCONER, Rob
University of Bradford
Bradford West Yorkshire BD7 1DP / GB
04 / PATTERSON, Laurence
University of Bradford
Bradford West Yorkshire BD7 1DP / GB
05 / ATKINSON, Jennifer
36a Church Street
Needingworth Cambridgeshire PE27 4TB / GB
06 / BIBBY, Mike
University of Bradford
Bradford West Yorkshire BD7 1DP / GB
 [2009/52]
Representative(s)Finnie, Isobel Lara, et al
Haseltine Lake LLP
Lincoln House, 5th Floor
300 High Holborn
London WC1V 7JH / GB
[2016/08]
Former [2013/16]Mintz Levin Cohn Ferris Glovsky and Popeo LLP
Alder Castle
10 Noble Street
London EC2V 7JX / GB
Former [2013/15]Finnie, Isobel Lara
Mintz Levin Cohn Ferris Glovsky &
Popeo LLP
Alder Castle
10 Noble Street
London EC2V 7JX / GB
Former [2009/52]O'Neill, Michelle, et al
Harrison IP Limited Marlborough House Westminster Place York Business Park
Nether Poppleton, York YO26 6RW / GB
Application number, filing date08718877.727.03.2008
[2009/52]
WO2008GB01043
Priority number, dateGB2007000703412.04.2007         Original published format: GB 0707034
[2009/52]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008125800
Date:23.10.2008
Language:EN
[2008/43]
Type: A2 Application without search report 
No.:EP2134372
Date:23.12.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2008 takes the place of the publication of the European patent application.
[2009/52]
Type: B1 Patent specification 
No.:EP2134372
Date:24.02.2016
Language:EN
[2016/08]
Search report(s)International search report - published on:EP04.12.2008
ClassificationIPC:A61K47/48, C07K7/06, A61P35/00, A61P29/02, A61P9/08
[2009/52]
CPC:
C07K7/06 (EP,US); A61K47/64 (US); A61K31/165 (EP,US);
A61K31/704 (EP,US); A61K47/55 (US); A61K47/60 (US);
A61K47/65 (EP,US); A61P17/02 (EP); A61P29/00 (EP);
A61P29/02 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/04 (EP); A61P9/08 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/08]
Former [2009/52]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:MMP-AKTIVIERTE GEFÄSSSCHÄDIGENDE MITTEL[2009/52]
English:MMP ACTIVATED VASCULAR DISRUPTING AGENTS[2009/52]
French:AGENTS PERTURBATEURES DU SYSTEME VASCULAIRE ACTIVES PAR MMP[2009/52]
Entry into regional phase01.10.2009National basic fee paid 
01.10.2009Designation fee(s) paid 
01.10.2009Examination fee paid 
Examination procedure01.10.2009Amendment by applicant (claims and/or description)
01.10.2009Examination requested  [2009/52]
24.03.2010Despatch of a communication from the examining division (Time limit: M06)
14.01.2011Reply to a communication from the examining division
14.12.2011Despatch of a communication from the examining division (Time limit: M06)
31.07.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
28.09.2012Reply to a communication from the examining division
11.04.2013Despatch of a communication from the examining division (Time limit: M06)
09.10.2013Reply to a communication from the examining division
30.04.2014Despatch of a communication from the examining division (Time limit: M04)
29.08.2014Reply to a communication from the examining division
04.08.2015Communication of intention to grant the patent
10.12.2015Fee for grant paid
10.12.2015Fee for publishing/printing paid
10.12.2015Receipt of the translation of the claim(s)
Divisional application(s)EP12160556.2  / EP2481428
EP12160565.3  / EP2481429
EP18156526.8  / EP3348282
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.03.2010
Opposition(s)25.11.2016No opposition filed within time limit [2017/05]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
28.09.2012Request for further processing filed
28.09.2012Full payment received (date of receipt of payment)
Request granted
22.10.2012Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
14.01.2011Request for further processing filed
14.01.2011Full payment received (date of receipt of payment)
Request granted
31.01.2011Decision despatched
Fees paidRenewal fee
11.03.2010Renewal fee patent year 03
09.03.2011Renewal fee patent year 04
07.03.2012Renewal fee patent year 05
06.02.2013Renewal fee patent year 06
12.03.2014Renewal fee patent year 07
09.03.2015Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY24.02.2016
EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
MC24.02.2016
SI24.02.2016
SK24.02.2016
TR24.02.2016
MT31.03.2016
BG24.05.2016
GR25.05.2016
[2018/31]
Former [2018/28]CY24.02.2016
EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
MC24.02.2016
MT24.02.2016
SI24.02.2016
SK24.02.2016
BG24.05.2016
GR25.05.2016
Former [2017/47]EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
MT24.02.2016
SI24.02.2016
SK24.02.2016
BG24.05.2016
GR25.05.2016
Former [2017/15]EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
SI24.02.2016
SK24.02.2016
BG24.05.2016
GR25.05.2016
Former [2016/50]EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
SK24.02.2016
GR25.05.2016
Former [2016/49]EE24.02.2016
HR24.02.2016
LT24.02.2016
LV24.02.2016
GR25.05.2016
Former [2016/39]HR24.02.2016
LT24.02.2016
LV24.02.2016
GR25.05.2016
Former [2016/36]HR24.02.2016
LT24.02.2016
GR25.05.2016
Former [2016/35]HR24.02.2016
GR25.05.2016
Cited inInternational search[X]WO0168145  (DU PONT PHARM CO [US]) [X] 1-16,22-47 * examples 21,121 *;
 [X]WO02072620  (UNIV NAPIER [GB], et al) [X] 1-16,22-47 * examples *;
 [Y]WO2005023314  (SQUIBB BRISTOL MYERS CO [US], et al) [Y] 1-16,22-47 * the whole document *;
 [X]WO2006110476  (MEDAREX INC [US], et al) [X] 1-16,22-47 * page 30, line 1 - line 16 *;
 [X]  - ALBRIGHT C F ET AL, "Matrix-metallloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20050501), vol. 4, no. 5, ISSN 1535-7163, pages 751 - 760, XP002456667 [X] 1-19,22-47 * Figure 1; Table 1, entry 6 *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-05-0006
 [X]  - KLINE T ET AL, "Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, (20040112), vol. 1, no. 1, ISSN 1543-8384, pages 9 - 22, XP007902392 [X] 1-16,22-47 * page 10, column R, line 13 *

DOI:   http://dx.doi.org/10.1021/mp0340183
 [X]  - KRATZ F ET AL, "Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, (20010806), vol. 11, no. 15, ISSN 0960-894X, pages 2001 - 2006, XP002208108 [X] 1-16,22-47 * Schemes 1, 2 *

DOI:   http://dx.doi.org/10.1016/S0960-894X(01)00354-7
 [X]  - MANSOUR AHMED M ET AL, "A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20030715), vol. 63, no. 14, ISSN 0008-5472, pages 4062 - 4066, XP002360787 [X] 1-16,22-47 * figure 1 *
 [X]  - KRATZ F ET AL, "PRODRUGS OF ANTHRACYCLINES IN CANCER CHEMOTHERAPY", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, (20060101), vol. 13, no. 5, ISSN 0929-8673, pages 477 - 523, XP009066220 [X] 1-16,22-47 * page 503 *

DOI:   http://dx.doi.org/10.2174/092986706776055751
 [X]  - CHAU Y ET AL, "SYNTHESIS AND CHARACTERIZATION OF DEXTRAN-PEPTIDE-METHOTREXATE CONJUGATES FOR TUMOR TARGETING VIA MEDIATION BY MATRIX METALLOPROTEINASE II AND MATRIX METALLOPROTEINASE IX", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, (20040701), vol. 15, no. 4, ISSN 1043-1802, pages 931 - 941, XP001236871 [X] 1-16,22-47 * abstract *

DOI:   http://dx.doi.org/10.1021/bc0499174
 [Y]  - DUBOWCHIK G M ET AL, "Receptor-mediated and enzyme-dependent trageting of cytotoxic anticancer drugs", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, (19990101), vol. 83, ISSN 0163-7258, pages 67 - 123, XP002391774 [Y] 1-16,22-47 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0163-7258(99)00018-2
 [Y]  - DAVIS P D ET AL, "ZD6126: A NOVEL VASCULAR-TARGETING AGENT THAT CAUSES SELECTIVE DESTRUCTION OF TUMOR VASCULATURE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (20021215), vol. 62, no. 24, ISSN 0008-5472, pages 7247 - 7253, XP001206293 [Y] 1-16,22-47 * the whole document *
ExaminationWO2006090813
    - "Product Monograph MMP Matrix Metalloproteinases", (20070501), XP055014029
    - HAMEL E, "ANTIMITOTIC NATURAL PRODUCTS AND THEIR INTERACTIONS WITH TUBULIN", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, (19960101), vol. 16, no. 2, doi:10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.0.CO;2-4, ISSN 0198-6325, pages 207 - 232, XP000886279

DOI:   http://dx.doi.org/10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.0.CO;2-4
    - E. O. Esbolaev ET AL, "C-10 AMINO ACID DERIVATIVES OF COLCHICINE", Chemistry of Natural Compounds, (19920501), vol. 28, no. 3-4, doi:10.1007/BF00630252, ISSN 0009-3130, pages 325 - 328, XP055058017

DOI:   http://dx.doi.org/10.1007/BF00630252
    - ESBOLAEV, E. O. ET AL, "C-10 DIPEPTIDE DERIVATIVES OF COLCHICINE", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1990:56641, URL: STN
    - ESBOLAEV, E. O. ET AL, "C-10 DIPEPTIDE DERIVATIVES OF COLCHICINE", KHIMIYA PRIRODNYKH SOEDINENII , (1), 91-5 CODEN: KPSUAR; ISSN: 0023-1150, (1989), XP008161090
    - ESBOLAEV, E. O. ET AL, "Cytotoxic activity of dipeptide derivatives of colchicine", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1990:69417, URL: STN
    - ESBOLAEV, E. O. ET AL, "Cytotoxic activity of dipeptide derivatives of colchicine", IZVESTIYA AKADEMII NAUK KAZAKHSKOI SSR, SERIYA BIOLOGICHESKAYA , (5), 83-6 CODEN: IKABAR; ISSN: 0002-3183, (1989), XP008161093
    - AITOZHINA N A ET AL, "[C10-aminoderivatives of colchicine: synthesis, structure and biological activity].", BIOORGANICHESKAIA KHIMIIA MAY 1996, (199605), vol. 22, no. 5, ISSN 0132-3423, pages 383 - 386, XP008161064
    - Dietmar Siemann ET AL, "Differentiation and definition of vascular-targeted therapies.", Clinical Cancer Research, (20050101), vol. 11, no. 2, ISSN 1078-0432, pages 416 - 420, XP055058046
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.